Treatment with insulin analog X10 and IGF-1 increases growth of colon cancer allografts

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Hvid, Henning ^a   Blouin, Marie José ^b   Birman, Elena ^b   Damgaard, Jesper ^a   Poulsen, Fritz ^a   Fels, Johannes Josef ^a   Fledelius, Christian ^a   Hansen, Bo Falck ^a   Pollak, Michael ^b  

^a NOVO NORDISK A S   (Denmark)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; COLONIC NEOPLASMS; HUMANS; INSULIN; INSULIN, REGULAR, HUMAN; INSULIN-LIKE GROWTH FACTOR I; MICE; RECEPTOR, IGF TYPE 1;

EID: 84894182045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079710     Document Type: Article

References (52)

1. Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, et al. (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2: 307-314.
2. Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4: 579-591. 10.1038/nrc1408 [doi];nrc1408 [pii].
3. Chen J (2011) Multiple signal pathways in obesity-associated cancer. Obes Rev 12: 1063-1070. 10.1111/j.1467-789X.2011.00917.x [doi].
4. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159: 1160-1167. 10.1093/aje/kwh161 [doi];159/12/1160 [pii].
5. Ogunleye AA, Ogston SA, Morris AD, Evans JM (2009) A cohort study of the risk of cancer associated with type 2 diabetes. Br J Cancer 101: 1199-1201. 6605240 [pii];10.1038/sj.bjc.6605240 [doi].
6. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, et al. (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744. 10.1007/s00125-009-1418-4 [doi].
7. Smith U, Gale EA (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52: 1699-1708. 10.1007/s00125-009-1441-5 [doi].
8. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, et al. (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328. 10.1056/NEJMoa1203858 [doi].
9. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, et al. (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679-682. 10.1038/333679a0 [doi].
10. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, et al. (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999-1005. (Pubitemid 30349423)
11. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, et al. (1997) Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40 Suppl 2: S54-S61. (Pubitemid 27306923)
12. Hansen BF, Danielsen GM, Drejer K, Sorensen AR, Wiberg FC, et al. (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315 (Pt 1): 271-279. (Pubitemid 26113562)
13. Hansen BF, Glendorf T, Hegelund AC, Lundby A, Lutzen A, et al. (2012) Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One 7: e34274. 10.1371/journal.pone. 0034274 [doi];PONE-D-11-22279 [pii].
14. Gammeltoft S, Hansen BF, Dideriksen L, Lindholm A, Schaffer L, et al. (1999) Insulin aspart: a novel rapid-acting human insulin analogue. Expert Opin Investig Drugs 8: 1431-1442. 10.1517/13543784.8.9.1431 [doi].
15. Dideriksen LH, Jorgensen LN, Drejer K (1992) Carcinogenic effects on female rats after 12 months administration of insulin analog b10 asp. Diabetes 41: 143A.
16. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54: 2226-2231. 10.1007/s00125-011-2203-8 [doi].
17. Koohestani N, Chia MC, Pham NA, Tran TT, Minkin S, et al. (1998) Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy. Carcinogenesis 19: 1679-1684. (Pubitemid 28441873)
18. Tran TT, Gupta N, Goh T, Naigamwalla D, Chia MC, et al. (2003) Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev 12: 47-56. (Pubitemid 36110157)
19. Lee WM, Lu S, Medline A, Archer MC (2001) Susceptibility of lean and obese Zucker rats to tumorigenesis induced by N-methyl-N-nitrosourea. Cancer Lett 162: 155-160. S0304383500006352 [pii].
20. Weber RV, Stein DE, Scholes J, Kral JG (2000) Obesity potentiates AOM-induced colon cancer. Dig Dis Sci 45: 890-895. (Pubitemid 30238248)
21. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M (2008) Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-839. ERC-08-0038 [pii];10.1677/ERC-08-0038 [doi].
22. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M (2010) Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17: 351-360. ERC-09-0252 [pii];10.1677/ERC-09-0252 [doi].
23. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, et al. (2012) Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 14: R8. bcr3089 [pii];10.1186/bcr3089 [doi].
24. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D (2010) Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes 59: 686-693. db09-1291 [pii];10.2337/db09-1291 [doi].
25. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, et al. (2010) Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70: 741-751. 0008-5472.CAN-09-2141 [pii];10.1158/0008-5472.CAN-09-2141 [doi].
26. Tran TT, Medline A, Bruce WR (1996) Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 5: 1013-1015. (Pubitemid 26415875)
27. Heuson JC, Legros N, Heimann R (1972) Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats. Cancer Res 32: 233-238.
28. Tran TT, Naigamwalla D, Oprescu AI, Lam L, McKeown-Eyssen G, et al. (2006) Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. Endocrinology 147: 1830-1837. en.2005-1012 [pii];10.1210/en.2005-1012 [doi].
29. Nagel JM, Staffa J, Renner-Muller I, Horst D, Vogeser M et al. (2010) Insulin glargine and NPH insulin increase to a similar degree epithelial cell proliferation and aberrant crypt foci formation in colons of diabetic mice. Horm Cancer 1: 320-330. 10.1007/s12672-010-0020-z [doi].
30. EMEA/CPMP (2001) Points To Consider Document on the Non-clinical Assessement of the Carcinogenic Potential of Insulin Analouges. CPMP/SWP/372/01.
31. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21: 171-179. 10.1080/10915810290096306 [doi]. (Pubitemid 34803492)
32. Tennekes H, Gembardt C, Dammann M, van RB (2004) The stability of historical control data for common neoplasms in laboratory rats: adrenal gland (medulla), mammary gland, liver, endocrine pancreas, and pituitary gland. Regul Toxicol Pharmacol 40: 18-27. 10.1016/j.yrtph.2004.04.003 [doi];S0273230004000339 [pii].
33. Hansen BF (2008) Insulin analogues with increased mitogenic potency-are they safe? Horm Metab Res 40: 431-433. 10.1055/s-2008-1062740 [doi].
34. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM (2000) Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 284: 1954-1961. joc90997 [pii].
35. Tsoi KK, Ng SS, Leung MC, Sung JJ (2008) Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia. Aliment Pharmacol Ther 28: 353-363. APT3726 [pii];10.1111/j.1365-2036.2008. 03726.x [doi].
36. Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, et al. (2012) Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocr Relat Cancer 19: 557-574. ERC-12-0125 [pii];10.1530/ERC-12-0125 [doi].
37. Poulsen F, Jensen KB (2007) A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 12: 240-247. 1087057106297566 [pii];10.1177/1087057106297566 [doi].
38. Poulsen F (2012) Wash-LOCI - A Semi-Heterogeneous Version of the LOCI Technology Allowing Removal of Unbound Material After Each Assay Step. In: Abuelzein E, editors. Trends in Immunolabelled and Related Techniques. INTECH. 259-274.
39. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439.
40. Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, et al. (2010) Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett 289: 246-253. S0304-3835(09)00537-0 [pii];10.1016/j.canlet.2009.08. 021 [doi].
41. Bibby BM, Martinussen T, Skovgaard IM (2004) Experimental Design in the Agricultural Sciences. Copenhagen: Samfundslitteratur.
42. Oleksiewicz MB, Bonnesen C, Hegelund AC, Lundby A, Holm GM, et al. (2011) Comparison of intracellular signalling by insulin and the hypermitogenic AspB10 analogue in MCF-7 breast adenocarcinoma cells. J Appl Toxicol 31: 329-341. 10.1002/jat.1590 [doi].
43. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470. (Pubitemid 29418240)
44. Hvid H, Fels JJ, Kirk RK, Thorup I, Jensen HE, et al. (2011) In situ phosphorylation of Akt and ERK1/2 in rat mammary gland, colon, and liver following treatment with human insulin and IGF-1. Toxicol Pathol 39: 623-640. 0192623311406936 [pii];10.1177/0192623311406936 [doi].
45. Zapf J, Hauri C, Waldvogel M, Froesch ER (1986) Acute metabolic effects and half-lives of intravenously administered insulinlike growth factors I and II in normal and hypophysectomized rats. J Clin Invest 77: 1768-1775. 10.1172/JCI112500 [doi]. (Pubitemid 16062628)
46. Listov-Saabye N, Jensen MB, Kiehr B, Hansen EW, Svendsen JE, et al. (2009) MCF-7 human mammary adenocarcinoma cells exhibit augmented responses to human insulin on a collagen IV surface. J Appl Toxicol 29: 470-477. 10.1002/jat.1428 [doi].
47. FDA (2005) Pharmacology/Toxicology Review and Evaluation, NDA N. 21839.
48. Tennagels N, Welte S, Hofmann M, Brenk P, Schmidt R, et al. (2013) Differences in metabolic and mitogenic signalling of insulin glargine and insulin aspart B10 in rats. Diabetologia 56: 1826-1834. 10.1007/s00125-013-2923- z [doi].
49. Bader AG, Kang S, Zhao L, Vogt PK (2005) Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 5: 921-929. nrc1753 [pii];10.1038/nrc1753 [doi].
50. Petroulakis E, Mamane Y, Le BO, Shahbazian D, Sonenberg N (2006) mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94: 195-199. 6602902 [pii];10.1038/sj.bjc.6602902 [doi].
51. Stephens L, Williams R, Hawkins P (2005) Phosphoinositide 3-kinases as drug targets in cancer. Curr Opin Pharmacol 5: 357-365. S1471-4892(05)00083-4 [pii];10.1016/j.coph.2005.03.002 [doi].
52. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J (2008) Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295: E1323- E1332. 90617.2008 [pii];10.1152/ajpendo.90617.2008 [doi].